Bortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review

Oncology Letters

Volumn 4, Issue 2, 2012, Pages 262-264

  Liu, Shuyan ^a   Yuan, Zhengang ^a   Zhang, Chunyang ^a   Fu, Weijun ^a   Hou, Jian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angioimmunoblastic T cell lymphoma; Bortezomib; Refractory; Relapsed; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MITOXANTRONE; PREDNISOLONE; THALIDOMIDE; VINCRISTINE;

AGED; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; BONE MARROW BIOPSY; BONE MARROW EXAMINATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; CELL PROLIFERATION; CERVICAL LYMPHADENOPATHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG INFECTION; LYMPHOID HYPERPLASIA; MEDIASTINUM LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; PHARYNX DISEASE; PHARYNX STENOSIS; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REMISSION; SORE THROAT; SPLENOMEGALY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84861996101     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.724     Document Type: Article

References (16)

1. Vose J, Armitage J and Weisenburger D; International T-Cell Lymphoma Project: International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26: 4124-4130, 2008.
2. Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, FellerA, Meijer CJ, Emile JF, Bouabdallah R, Bosly A, Diebold J, Haioun C, Coiffier B, Gisselbrecht C, Gaulard P; Groupe d'Etude des Lymphomes de l'Adulte: Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 111: 4463-4470, 2008.
3. de Leval L, Gisselbrecht C and Gaulard P: Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 148: 673-689, 2010.
4. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, et al: Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110: 2316-2323, 2007.
5. d'Amore F, Radford J, Relander T, Jerkeman M, Tilly H, OsterborgA, Morschhauser F, Gramatzki M, Dreyling M, BangB and Hagberg H: Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol 150: 565-573, 2010.
6. Dang NH, Pro B, Hagemeister FB, Samaniego F, JonesD, SamuelsBI, Rodriguez MA, Goy A, Romaguera JE, McLaughlinP, et al: Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br JHaematol 136: 439-447, 2007.
7. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, PopplewellL, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, GisselbrechtC, et al: Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29: 1182-1189, 2011.
8. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, AllenSL, Jaffe ES, Ling A, Turner M, Peer CJ, et al: Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117: 5827-5834, 2011.
9. Advani R, Horwitz S, Zelenetz A and Horning SJ: Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma 48: 521-525, 2007.
10. Gottardi M, Danesin C, Canal F, Dei Tos AP, Stefani PM, Calistri E, Salvadori U and Gherlinzoni F: Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation. Leuk Lymphoma 49: 1836-1838, 2008.
11. Arkenau HT, Chong G, Cunningham D, Watkins D, Sirohi B, Chau I, Wotherspoon A, Norman A, Horwich A and Matutes E: Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92: 271-272, 2007.
12. Lee J, Suh C, Kang HJ, Ryoo BY, Huh J, Ko YH, Eom HS, Kim K, Park K and Kim WS: Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 19: 2079-2083, 2008.
13. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, SausvilleE, Adams J, Elliott P and Van Waes C: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7: 1419-1428, 2001.
14. Zhao WL, Liu YY, Zhang QL, Wang L, Leboeuf C, Zhang YW, Ma J, Garcia JF, Song YP, Li JM, et al: PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. Blood 111: 3867-3871, 2008.
15. Shi WY, Wang L, Xiao D, Yao Y, Yang F, Jiang XX, LeboeufC, Janin A, Chen SJ and Zhao WL: Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma. Ann Hematol 90: 53-58, 2011.
16. Martínez-Delgado B, Cuadros M, Honrado E, Ruizde laParteA, Roncador G, Alves J, Castrillo JM, Rivas C, BenítezJ: Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 19: 2254-2263, 2005.